CCL2 and pancreatic neoplasm: The enhanced immuno-oncolytic virus efficacy of TPV/∆66R/mIL-2 and TPV/∆66R/mCCL-2 may be attributable to CCL-2- and IL-2-mediated negative regulation of pancreatic tumor progression through stimulation of the innate immune response.